Advertisement
Canada markets open in 9 hours 16 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7319
    -0.0002 (-0.02%)
     

  • CRUDE OIL

    83.42
    +0.06 (+0.07%)
     

  • Bitcoin CAD

    91,061.58
    +106.77 (+0.12%)
     

  • CMC Crypto 200

    1,434.05
    +19.29 (+1.36%)
     

  • GOLD FUTURES

    2,342.80
    +0.70 (+0.03%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,733.25
    +126.50 (+0.72%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,410.97
    +858.81 (+2.29%)
     

  • CAD/EUR

    0.6833
    -0.0003 (-0.04%)
     

Heat Biologics CEO to Present at the ThinkEquity Conference in New York City

ACCESSWIRE

DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that Jeff Wolf, Chief Executive Officer, is scheduled to present at the ThinkEquity Conference on Thursday, May 2nd, at 8:00 AM Eastern Time, which is being held at The Mandarin Oriental Hotel in New York City.

Additional information on the conference is available at, https://www.think-equity.com/thinkequity-conference.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform ("TCAP") produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our ComPACT technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) and with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. For more information, please visit www.heatbio.com.

ADVERTISEMENT

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.



View source version on accesswire.com:
https://www.accesswire.com/542277/Heat-Biologics-CEO-to-Present-at-the-ThinkEquity-Conference-in-New-York-City